Limits...
Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats.

Qi Y, Shang JY, Ma LJ, Sun BB, Hu XG, Liu B, Zhang GJ - Respir. Res. (2014)

Bottom Line: Meanwhile, COPD also is associated with metabolic disorders, such as skeletal muscle weakness.Strikingly, activation of AMP-activated protein kinase (AMPK) exerts critical roles in energy metabolism.Such findings indicate that AMPK may serve as a target for therapeutic intervention in the treatment of muscle weakness in COPD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, Zhengzhou University People's Hospital (He'nan Provincial People's Hospital), 7 Weiwu Road, ZhengZhou, 450003, China. rose20000@126.com.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation and inflammation. Meanwhile, COPD also is associated with metabolic disorders, such as skeletal muscle weakness. Strikingly, activation of AMP-activated protein kinase (AMPK) exerts critical roles in energy metabolism. However, it remains unclear whether and how the expression levels of AMPK are affected in the COPD model rats which may lead to the dysfunction of the skeletal muscle in these rats.

Methods: Here we developed a rat model of COPD, and we investigated the morphological changes of peripheral skeletal muscle and measured the levels of tumor necrosis factor -α (TNF-α) and AMPK in skeletal muscle by using approaches that include immunohistochemistry and polymerase chain reaction (PCR).

Results: We found that the expression levels of both AMPK mRNA and protein in skeletal muscles were significantly reduced in the COPD model rats, in comparison to those from the control rats, the COPD model rats that received treatments with AICAR and resveratrol, whereas the expression levels of TNF-α were elevated in COPD rats.

Conclusion: Such findings indicate that AMPK may serve as a target for therapeutic intervention in the treatment of muscle weakness in COPD patients.

Show MeSH

Related in: MedlinePlus

Morphological changes of the skeletal muscle in control rats and COPD model rats that were treated with vehicles, AICAR or resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats with resveratrol treatment. Amplification ×200.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4265440&req=5

Fig3: Morphological changes of the skeletal muscle in control rats and COPD model rats that were treated with vehicles, AICAR or resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats with resveratrol treatment. Amplification ×200.

Mentions: Interestingly, we found that the skeletal muscle fibers became atrophy in the COPD model rats, in comparison to those in the control rats. We also observed that there were more collagen depositions in the COPD rats (Figure 3B). Importantly, we found that both resveratrol and AICAR decreased the depositions of collagen in the skeletal muscle tissue in the COPD model rats (Figure 3C and D). Furthermore, the number of mitochondria in triceps tissue of COPD model rats was reduced and the mitochondria became swelling complicated with more vacuoles and the dissolved endometrial and crest of the mitochondria (Figure 4B). More importantly, both resveratrol and AICAR ameliorated the abnormal changes of mitochondria as mentioned above in the COPD model rats (Figure 4C and D).Figure 3


Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats.

Qi Y, Shang JY, Ma LJ, Sun BB, Hu XG, Liu B, Zhang GJ - Respir. Res. (2014)

Morphological changes of the skeletal muscle in control rats and COPD model rats that were treated with vehicles, AICAR or resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats with resveratrol treatment. Amplification ×200.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4265440&req=5

Fig3: Morphological changes of the skeletal muscle in control rats and COPD model rats that were treated with vehicles, AICAR or resveratrol at week 20 (H & E stained). (A) Control rats; (B) COPD rats with vehicle; (C) COPD rats with AICAR treatment; and (D) COPD rats with resveratrol treatment. Amplification ×200.
Mentions: Interestingly, we found that the skeletal muscle fibers became atrophy in the COPD model rats, in comparison to those in the control rats. We also observed that there were more collagen depositions in the COPD rats (Figure 3B). Importantly, we found that both resveratrol and AICAR decreased the depositions of collagen in the skeletal muscle tissue in the COPD model rats (Figure 3C and D). Furthermore, the number of mitochondria in triceps tissue of COPD model rats was reduced and the mitochondria became swelling complicated with more vacuoles and the dissolved endometrial and crest of the mitochondria (Figure 4B). More importantly, both resveratrol and AICAR ameliorated the abnormal changes of mitochondria as mentioned above in the COPD model rats (Figure 4C and D).Figure 3

Bottom Line: Meanwhile, COPD also is associated with metabolic disorders, such as skeletal muscle weakness.Strikingly, activation of AMP-activated protein kinase (AMPK) exerts critical roles in energy metabolism.Such findings indicate that AMPK may serve as a target for therapeutic intervention in the treatment of muscle weakness in COPD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, Zhengzhou University People's Hospital (He'nan Provincial People's Hospital), 7 Weiwu Road, ZhengZhou, 450003, China. rose20000@126.com.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation and inflammation. Meanwhile, COPD also is associated with metabolic disorders, such as skeletal muscle weakness. Strikingly, activation of AMP-activated protein kinase (AMPK) exerts critical roles in energy metabolism. However, it remains unclear whether and how the expression levels of AMPK are affected in the COPD model rats which may lead to the dysfunction of the skeletal muscle in these rats.

Methods: Here we developed a rat model of COPD, and we investigated the morphological changes of peripheral skeletal muscle and measured the levels of tumor necrosis factor -α (TNF-α) and AMPK in skeletal muscle by using approaches that include immunohistochemistry and polymerase chain reaction (PCR).

Results: We found that the expression levels of both AMPK mRNA and protein in skeletal muscles were significantly reduced in the COPD model rats, in comparison to those from the control rats, the COPD model rats that received treatments with AICAR and resveratrol, whereas the expression levels of TNF-α were elevated in COPD rats.

Conclusion: Such findings indicate that AMPK may serve as a target for therapeutic intervention in the treatment of muscle weakness in COPD patients.

Show MeSH
Related in: MedlinePlus